Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] The company is in the fragmented segment. Perhaps due to this, it has posted declining margins amidst competition. Though based on its FY24 annualized earnings the issue appears reasonably priced, its only for the well-informed investors for parking funds for the medium term. The tiny paid-up equity capital post listing indicates longer gestation period for migration to mainboard. Read detail review...
Docmode Health Technologies Limited peer comparison with similar listed entities. (As on March 31, 2023)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Docmode Health Technologies Limited | 8.50 | 8.50 | 16.29 | 9.30 | 56.06 | 4.85 |
Docmode Health Technologies IPO Reviews, analysis and views by popular members. Read Docmode Health Technologies Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
Useful Articles
RHP